stockportfolio.pro
Stocks / ADMA vs NVCR
ADMA vs NVCR
ADMA Biologics, Inc. and NovoCure Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ADMA Biologics, Inc. (ADMA) | NovoCure Limited (NVCR) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $510.17M | $655.35M |
| Net income (latest FY) | $146.93M | $-136.23M |
| Revenue growth (5y CAGR) | 64.6% | 5.8% |
| Net margin | 28.8% | -20.8% |
| Return on equity | 30.8% | -40.0% |
| P/E ratio | 12.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADMA — free Open NVCR — freeFrequently asked questions
Which is bigger, ADMA or NVCR?
NovoCure Limited is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, ADMA or NVCR?
Over the last five fiscal years, ADMA Biologics, Inc. grew revenue faster — 64.6%/yr versus 5.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.